Carter's (CRI) Tops Q3 EPS by 27c ; Offers Guidance

Carter's (NYSE: CRI) reported Q3 EPS of $1.64, $0.47 better than the analyst estimate of $1.37. Revenue for the quarter came in at $758 million versus the consensus estimate of $751.9 million.

GUIDANCE:

Carter's sees FY2024 EPS of $4.70-$5.15, versus the consensus of $5.05. Carter's sees FY2024 revenue of $2.78-2.82 billion, versus the consensus of $2.81 billion.

Carter's sees Q4 2024 EPS of $1.32-$1.72, versus the consensus of $1.86. Carter's sees Q4 2024 revenue of $800-840 million, versus the consensus of $825.5 million.

For earnings history and earnings-related data on Carter's (CRI) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13